120 related articles for article (PubMed ID: 21871872)
41. Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.
Festoff BW; Suo Z; Citron BA
CNS Drugs; 2003; 17(10):699-717. PubMed ID: 12873154
[TBL] [Abstract][Full Text] [Related]
42. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis.
Dupuis L; Gonzalez de Aguilar JL; di Scala F; Rene F; de Tapia M; Pradat PF; Lacomblez L; Seihlan D; Prinjha R; Walsh FS; Meininger V; Loeffler JP
Neurobiol Dis; 2002 Aug; 10(3):358-65. PubMed ID: 12270696
[TBL] [Abstract][Full Text] [Related]
43. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries.
Taghibiglou C; Martin HG; Lai TW; Cho T; Prasad S; Kojic L; Lu J; Liu Y; Lo E; Zhang S; Wu JZ; Li YP; Wen YH; Imm JH; Cynader MS; Wang YT
Nat Med; 2009 Dec; 15(12):1399-406. PubMed ID: 19966780
[TBL] [Abstract][Full Text] [Related]
44. Iron is a potential key mediator of glutamate excitotoxicity in spinal cord motor neurons.
Yu J; Guo Y; Sun M; Li B; Zhang Y; Li C
Brain Res; 2009 Feb; 1257():102-7. PubMed ID: 19135430
[TBL] [Abstract][Full Text] [Related]
45. New drugs for ALS: how do we get there?
Glass JD
Exp Neurol; 2012 Jan; 233(1):112-7. PubMed ID: 22033032
[No Abstract] [Full Text] [Related]
46. How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis?
Odierna GL; Vucic S; Dyer M; Dickson T; Woodhouse A; Blizzard C
Brain; 2024 May; 147(5):1610-1621. PubMed ID: 38408864
[TBL] [Abstract][Full Text] [Related]
47. Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?
Lennon MJ; Jones SP; Lovelace MD; Guillemin GJ; Brew BJ
Neurotox Res; 2016 Feb; 29(2):201-7. PubMed ID: 26563995
[TBL] [Abstract][Full Text] [Related]
48. Medicine. Treating neurodegenerative diseases with antibiotics.
Miller TM; Cleveland DW
Science; 2005 Jan; 307(5708):361-2. PubMed ID: 15661995
[No Abstract] [Full Text] [Related]
49. The Serotonergic System and Amyotrophic Lateral Sclerosis: A Review of Current Evidence.
Yang L; Cheng Y; Zhu Y; Cui L; Li X
Cell Mol Neurobiol; 2023 Aug; 43(6):2387-2414. PubMed ID: 36729314
[TBL] [Abstract][Full Text] [Related]
50. Selective vulnerability of spinal motor neurons to reactive dicarbonyl compounds, intermediate products of glycation, in vitro: implication of inefficient glutathione system in spinal motor neurons.
Shinpo K; Kikuchi S; Sasaki H; Ogata A; Moriwaka F; Tashiro K
Brain Res; 2000 Apr; 861(1):151-9. PubMed ID: 10751575
[TBL] [Abstract][Full Text] [Related]
51. Neuroscientists seek answers to brain function and disease. Faulty protein linked to ALS.
Vogel G
Science; 1996 Dec; 274(5293):1612-3. PubMed ID: 8984628
[No Abstract] [Full Text] [Related]
52. ALS serum has no effect on three enzymatic activities in cultured human spinal cord neurons.
Touzeau G; Kato AC
Neurology; 1986 Apr; 36(4):573-6. PubMed ID: 3960335
[TBL] [Abstract][Full Text] [Related]
53. Merits of a new drug trial for ALS?
Beghi E; Bendotti C; Mennini T
Science; 2005 Apr; 308(5722):632-3; author reply 632-3. PubMed ID: 15864832
[No Abstract] [Full Text] [Related]
54. Brain glutamate deficiency in amyotrophic lateral sclerosis.
Perry TL; Hansen S; Jones K
Neurology; 1987 Dec; 37(12):1845-8. PubMed ID: 2891083
[TBL] [Abstract][Full Text] [Related]
55. Extracts of spinal cord from amyotrophic lateral sclerosis: effect on cultured neuron.
Iwasaki Y; Kinoshita M; Ikeda K; Shiojima T
Acta Neurol Scand; 1989 Sep; 80(3):264. PubMed ID: 2801024
[No Abstract] [Full Text] [Related]
56. Immunocytochemical method for investigating in vivo neuronal oxygen radical-induced lipid peroxidation.
Hall ED; Oostveen JA; Andrus PK; Anderson DK; Thomas CE
J Neurosci Methods; 1997 Oct; 76(2):115-22. PubMed ID: 9350962
[TBL] [Abstract][Full Text] [Related]
57. Trace element studies in amyotrophic lateral sclerosis (ALS).
Mitchell JD; East BW; Harris IA; Pentland B
Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 7():454-7. PubMed ID: 3776607
[No Abstract] [Full Text] [Related]
58. Excitotoxicity in ALS.
Leigh PN; Meldrum BS
Neurology; 1996 Dec; 47(6 Suppl 4):S221-7. PubMed ID: 8959993
[No Abstract] [Full Text] [Related]
59. A three-groups model for high-throughput survival screens.
Shaby BA; Skibinski G; Ando M; LaDow ES; Finkbeiner S
Biometrics; 2016 Sep; 72(3):936-44. PubMed ID: 26821783
[TBL] [Abstract][Full Text] [Related]
60. Hypothesis: gut as source of motor neuron toxin in the development of ALS.
Kaneko K; Hachiya NS
Med Hypotheses; 2006; 66(2):438-9. PubMed ID: 16236460
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
